|
|
|
| home > news > detailed info |
|
|
 INDUSTRY NEWS AND PRESS RELEASES |
Evonetix Appoints Colin McCracken as Chief Executive Officer |
 |
|
Cambridge, UK, 13 June 2022: EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the appointment of Colin McCracken as Chief Executive Officer with immediate effect. Colin’s appointment will support the next phase of the Company’s development and the commercialisation of its semiconductor-based DNA synthesis platform.
Colin brings over 20 years’ experience in commercial and business development roles. Prior to joining Evonetix he was Senior Vice President and Chief Commercial Officer at Fluidigm Corp, where he was responsible for leading all commercial activities, driving revenue growth, and expanding the Company’s global reach. He has delivered commercial success in numerous leadership positions, including Vice President and General Manager and Vice President of Sales at Thermo Fisher Scientific, Vice President and Head of European Sales at Life Technologies and National Sales Manager at Qiagen.
As CEO of Evonetix, Colin will focus on building strategic partnerships and customer relationships, ahead of the commercial introduction of the Company’s first product, a benchtop DNA printer. The announcement comes as Evonetix continues to strengthen its senior leadership team, following the recent appointment of Paul Beastall as Chair, as the Company enters the next phase of its development, moving from pure research and development into product commercialisation.
Colin McCracken, Chief Executive Officer at Evonetix, commented: “The team at Evonetix has achieved major milestones in building the technology to enable semiconductor based decentralised DNA synthesis. The Company’s technology has the potential to revolutionise synthetic biology, overcoming the limitations of centralised supply by making rapid synthesis of complex DNA libraries and genes routine in every lab. It is an honour to join Evonetix at this pivotal point in their development and I’m looking forward to working with the team to execute our vision and commercial strategy.”
Dr Matthew Hayes, Chief Technology Officer and Founder at Evonetix, commented: “We have engaged in an extensive and detailed search to find the right person to lead Evonetix into our next phase of development. Colin has impressed us with both his commercial knowledge and ability to relate to the leadership team and wider organisation. We are all looking forward to working with him and continuing to build Evonetix’s future.”
Paul Beastall, Chair of the Board at Evonetix, commented: “Not only does Colin bring immense experience in building commercial organisations and executing on business plans, he is also a creative and passionate team player, skilled in developing relationships and getting the most out of any organisation he works with. The Board is thrilled to have him join Evonetix, and we are confident that his expertise and drive will allow us to deliver on the immense potential of Evonetix’s synthesis platform. I would also like to take this opportunity to thank Matthew Hayes for his dedicated work as interim Chief Executive Officer, ensuring the smooth day-to-day running of the business. He will resume his role as Chief Technology Officer with the Company following a transition to Colin."
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Oxford BioTherapeutics Announces Research Collaboration with ImmunoGen to Develop Novel Antibody-Drug Conjugates
OXFORD, UK and SAN JOSE, California, 13/06/2022 - Oxford
BioTherapeutics (OBT), a clinical stage oncology company with a pipeline
of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies,
today announced a multi-year collaboration to research, develop and
commercialize novel, first-in-class ADCs with ImmunoGen (IMGN), a leader
in the expanding field of ADCs for the treatment of cancer. The
companies will utilize ImmunoGen’s linker-payload technology directed to
novel targets identified via OBT's proprietary OGAP® discovery
platform. The companies will support these R&D efforts through joint
funding and by combining their respective proprietary technologies.
More info >> |
|
 |
White Papers |
 |
|
BioT ULT Transporter
BioCision
The growth of biobanking, cell therapy, and complex biopharmaceutical therapies like cancer vaccines has created a strong need for products and processes to ensure the stability of temperature-sensitive biospecimens. Proper collection, handling, characterization, packaging and shipping of these materials is critical, as poor sample handling impacts researchers working on discovery with patient samples, as well as clinicians treating patients with cutting edge therapies.
This white paper describes in detail the BioCision BioT™ ULT Transporter, the first-of-its-kind dry ice-based portable cooling system that maintains a stable -75° to -50°C environment for over 24 hours on one charge of dry ice, enabling reliable handling and transfer of valuable temperature-sensitive biospecimens as part of a larger cold chain standardization process.
More info >> |
|
 |
Industry Events |
 |
Connect in Pharma
14-15 September 2022, Plaexpo, Geneva, Switzerland
The new event driving innovation for pharma and biopharma businesses,
Connect in Pharma will unite key players in Pharmaceutical and
Biopharmaceutical packaging and production in Geneva on 14 – 15
September 2022.
More info >> |
|
|
